GlobeNewswire

MYALEPTA® (metreleptin) Receives Positive CHMP Opinion in Patients with Generalized and Partial Lipodystrophy

Share

Europe represents potentially the largest market for metreleptin with expected authorization in both generalized and partial lipodystrophy

VANCOUVER, British Columbia, June 01, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the granting of marketing authorization, under exceptional circumstances, for MYALEPTA.

The CHMP recommends granting marketing authorization for MYALEPTA, as an adjunct to diet, as a replacement therapy to treat the complications of leptin deficiency in lipodystrophy (LD) patients with confirmed congenital generalized LD (Berardinelli-Seip syndrome); or acquired generalized LD (Lawrence syndrome) in adults and children 2 years of age and above; or with confirmed familial partial LD or acquired partial LD (Barraquer-Simons syndrome), in adults and children 12 years of age and above for whom standard treatments have failed to achieve adequate metabolic control.

The CHMP's positive opinion will now be reviewed by the European Commission (EC), which has the authority to grant approval of this indication. The Company anticipates a decision in mid-2018.  If approved by the EC, MYALEPTA, which has orphan drug designation in Europe, will be the first and only licensed treatment in the EU as an adjunct to diet as a replacement therapy to treat the complications of leptin deficiency in LD patients.

Murray Stewart, DM, FCRP, Executive Vice President, Head of Research & Development said,  "Lipodystrophy is a serious, rare condition, characterized by loss of fat tissue. In some patients it is inherited, while in others it may be acquired. This loss of fat tissue causes a deficit in the hormone leptin leading to possible metabolic complications such as hypertriglyceridemia, insulin resistance and hyperglycemia. This decision by the CHMP is welcomed by the physician community who is in need of treatment options for its generalized and partial lipodystrophy patients."

Chief Operating Officer Jeffrey Hackman said, "The positive CHMP opinion is a substantial milestone for our company, and even more importantly, for generalized and partial lipodystrophy patients. Europe is a significant market with a meaningful number of generalized and partial lipodystrophy patients already being treated through the metreleptin early access program. Assuming EC approval, we look forward to the opportunity to work with physicians, payers and patient organizations to convert these patients to commercial patients and to reach even more generalized and partial lipodystrophy patients in need."

In accordance with the receipt of a marketing authorization under exceptional circumstances, certain risk minimization measures and post-authorization obligations will be required, including proposed studies which will further the understanding of MYALEPTA's impact on patients with generalized and partial lipodystrophy.

About Lipodystrophy

LD syndromes are ultra-rare disorders characterized by the irreversible loss of adipose tissue. In patients with lipodystrophy syndromes, levels of leptin are often very low. Leptin is a naturally occurring hormone produced in adipose tissue and is an important regulator of energy homoeostasis, fat and glucose metabolism, reproductive capacity, and other diverse physiological functions.

With generalized lipodystrophy, the loss of fat affects the whole body. With partial lipodystrophy, the loss of fat typically occurs in the arms, legs, head, and trunk regions, while accumulation of fat may occur in other areas of the body, including the neck, face, and intra-abdominal regions.

MYALEPT, the U.S. brand name of metreleptin, is approved in the U.S. to treat generalized lipodystrophy, but is not approved to treat partial lipodystrophy.

FOR IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING IN THE U.S., PLEASE VISIT WWW.MYALEPT.COM    

About Novelion Therapeutics

Novelion Therapeutics is a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases. The company seeks to advance its portfolio of rare disease therapies by investing in science and clinical development. Novelion has a commercial portfolio of products through its indirect subsidiary, Aegerion Pharmaceuticals, Inc. 

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" of Novelion within the meaning of applicable laws and regulations and constitute "forward-looking information" within the meaning of applicable securities laws. Any statements contained herein which do not describe historical facts, including statements regarding expectations and beliefs about the EC's approval decision, including timing, the size of the market for MYALEPTA in the EU, and converting early access patients to commercial patients and adding new MYALEPTA patients in the EU, are forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Such risks and uncertainties include, among others, those risks identified in our filings with the U.S. Securities and Exchange Commission (the "SEC"), including under the heading "Risk Factors" in our Annual Report on Form 10-K filed on March 16, 2018, and subsequent filings, with the SEC, available on the SEC's website at www.sec.gov. Any such risks and uncertainties could materially and adversely affect our results of operations and cash flows, which would, in turn, have a significant and adverse impact on our stock price. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Except as required by law, we undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

Investors and others should note that we communicate with our investors and the public using our company website, www.novelion.com, including, but not limited to, company disclosures, investor presentations and FAQs, SEC filings, press releases, public conference call transcripts and webcast transcripts. The information that we post on this website could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

CONTACT:

Amanda Murphy, Director, Investor Relations & Corporate Communications
Novelion Therapeutics
857-242-5024
amanda.murphy@novelion.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novelion Therapeutics Inc. via Globenewswire

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Vostok Emerging Finance buybacks during w.2923.7.2019 08:00:00 CESTPress release

Stockholm, July 23, 2019 (GLOBE NEWSWIRE) -- During the period July 15, 2019 until July 19, 2019, Vostok Emerging Finance Ltd (“VEF” or the “Company”) has repurchased in total 488,247 Swedish Depository Receipts (SDRs). The share buybacks have been made within the USD 5m buyback program announced by the Company on March 4, 2019. SDRs have been repurchased as follows during this period: Date Aggregated daily volume (number of SDRs) Weighted average SDR price per day (SEK) Total daily transaction value (SEK) July 15, 2019 95,700 2.47 235,962 July 16, 2019 97,500 2.45 239,125 July 17, 2019 104,000 2.47 256,835 July 18, 2019 106,000 2.45 259,811 July 19, 2019 85,047 2.48 210,715 All trades have been carried out on Nasdaq First North Stockholm by Pareto Securities AB on behalf of VEF. Following the above acquisitions, VEF holds 2,718,218 repurchased SDRs in the Company, and the total number of outstanding SDRs of the Company excluding repurchased SDRs is 658,777,777 and including repurchase

Better Collective acquires US market leading sports betting brands; VegasInsider.com and ScoresandOdds.com23.7.2019 08:00:00 CESTPress release

Regulatory Release 21/2019 Better Collective has, through a wholly-owned US subsidiary, completed the acquisition of the assets of Florida based Vegasinsider.com and Scoresandodds.com for a total transaction price of 20 million USD to be paid in cash. Better Collective, the world’s leading sports betting affiliate, has acquired two of the leading sports betting websites in the United States (US). The brands have been market leading within sports betting information for more than 20 years and are expected to become market leading affiliate websites in those states where online sports betting is available. During the National Football League (NFL) 2018/2019 season, the two websites generated more than 15 million unique visits per month. Changing the business model With the aim of empowering sports bettors worldwide, Better Collective is adding the two websites to its portfolio of sites to educate and entertain users in the US as various states are beginning to regulate online sports bett

Vostok Emerging Finance buybacks during w.2923.7.2019 08:00:00 CESTPressemelding

Stockholm, July 23, 2019 (GLOBE NEWSWIRE) -- During the period July 15, 2019 until July 19, 2019, Vostok Emerging Finance Ltd (“VEF” or the “Company”) has repurchased in total 488,247 Swedish Depository Receipts (SDRs). The share buybacks have been made within the USD 5m buyback program announced by the Company on March 4, 2019. SDRs have been repurchased as follows during this period: Date Aggregated daily volume (number of SDRs) Weighted average SDR price per day (SEK) Total daily transaction value (SEK) July 15, 2019 95,700 2.47 235,962 July 16, 2019 97,500 2.45 239,125 July 17, 2019 104,000 2.47 256,835 July 18, 2019 106,000 2.45 259,811 July 19, 2019 85,047 2.48 210,715 All trades have been carried out on Nasdaq First North Stockholm by Pareto Securities AB on behalf of VEF. Following the above acquisitions, VEF holds 2,718,218 repurchased SDRs in the Company, and the total number of outstanding SDRs of the Company excluding repurchased SDRs is 658,777,777 and including repurchase

Idorsia announces financial results for the first half of 201923.7.2019 07:00:00 CESTPress release

Allschwil, Switzerland – July 23, 2019 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first half of 2019. Key figures US GAAP operating expenses HY 2019 at CHF 252 million Non-GAAP operating expenses HY 2019 at CHF 234 million Unchanged guidance for 2019: US GAAP operating expenses of around CHF 570 million and non-GAAP operating expenses of around CHF 530 million (both measures exclude any potential milestone payments) Jean-Paul Clozel, MD and Chief Executive Officer, commented: “The first half of 2019 has been about running our studies and getting ready for the wave of results and news flow approaching soon. All departments are getting ready for the potential filing of our late stage assets. With the appointment of Simon Jose as Chief Commercial Officer the hiring of a core commercial team has begun, enabling the development of a commercial business plan. We expect to receive the first set of pivotal data in the first half of 2020.” Financial results US GAAP re

SIKA EXPANDS MORTAR PLANT IN SERBIA23.7.2019 07:00:00 CESTPress release

SIKA EXPANDS MORTAR PLANT IN SERBIA Sika is expanding its production capacities in Southeast Europe by bringing a further mortar facility as well as a warehouse for raw materials and end-products on stream at its Simanovci site in Serbia. The plant, which is located near Belgrade, has been continuously expanded in recent years to keep pace with the dynamic development experienced by the region’s construction sector and strong Sika growth. The expanded production capacities and new warehouse will enable Sika to continue to successfully penetrate the growing construction markets in Southeast Europe. The high-quality ready-mixed mortars produced at the site are distributed primarily to builders’ merchants. As well as catering for the domestic market, the ultra-modern plant also acts as a regional production hub for Sika national subsidiaries in the neighboring countries Croatia, Slovenia, Hungary, Bosnia and Herzegovina, and Bulgaria. Ivo Schädler, EMEA Regional Manager: “By investing in

Norsk Hydro: Second quarter 2019: Results down on lower realized prices23.7.2019 06:59:00 CESTPress release

Hydro's underlying earnings before financial items and tax was NOK 875 million in the second quarter, down from NOK 2,713 million in the same quarter last year. This mainly reflected lower realized aluminium and alumina prices and effects from the cyber-attack, partly offset by positive currency effects. Underlying EBIT of NOK 875 million Ramp-up progressing successfully at Alunorte, Paragominas and Albras Bauxite & Alumina up on increased production and currency, mostly offset by lower realized alumina prices Primary Metal down on lower realized aluminium price Financial impact of cyber-attack estimated to NOK 250-300 million in Q2 – main impact in Extruded Solutions Downstream results down on margin and volume, reflecting softening demand Energy down on lower volumes 2019 global primary aluminium market expected in deficit, demand growth expectations for 2019 reduced to 1-2% Underlying EBIT for Bauxite & Alumina increased compared to the second quarter of last year, from NOK 364 mill